National Minority AIDS Council Building Healthier Communities

Building Leadership in Communities of Color to Address HIV/AIDS

Women of Color Leadership Institute

HIV Vaccine Research in the Media

NMAC Executive Director, Paul Kawata, featured in POZ Special Report, Rallying Behind HIV Vaccine Research

Expert Urges AIDS Vaccine Research

In a Wall Street Journal opinion piece (online.wsj.com, 4/25) published April 25, Seth Berkley, MD, president and CEO of the International AIDS Vaccine Initiative, addresses the need for continued vaccine research following recent disappointing trials.

While many AIDS experts have suggested that funding be targeted less toward HIV vaccine research and more toward treating the virus—particularly following Merck’s vaccine trial cancellation last year—Dr. Berkley writes that vaccine research remains essential and should not be abandoned.

The National Minority AIDS Council Honors HIV Vaccine Awareness Day This Sunday, May 18, 2008 by Launching New Online Materials and Poster Contest

Blacks Willing To Participate in Medical Research Despite Awareness of Tuskegee Study, According to Research

California Researcher Offers HIV Vaccine Database

Commitment To Conducting More Basic Research in Search for HIV/AIDS Vaccine 'Prudent,' Editorial Says

U.S., British HIV/AIDS Researchers Pessimistic About Prospects of Vaccine, Survey Finds

'Sound Scientific Reasons To Believe' Researchers Can Create HIV/AIDS Vaccine, Opinion Piece Says

Early Findings Show Tantalizing Promise for Therapeutic HIV Vaccine

Biotech Firm GeoVax Labs To Launch Phase II Trials of HIV Vaccine Candidate

Increased Research, Determination Needed in HIV/AIDS Vaccine Efforts, HIV Vaccine Enterprise Head Says

Report Reviews Developments in HIV/AIDS Vaccine Research

NMAC Honors National HIV Vaccine Awareness Day with New Online Materials and a Poster Contest

HIV Vaccine Awareness Day

The Long, Hard March Toward an HIV Vaccine Continues

The Search Must Go On, Vaccine Advocates Say

Paul Kawata Featured in Poz Article, Rallying Behind HIV Vaccine Research

Advocates Call for Increased Funding, Renewed Efforts for HIV/AIDS Vaccine Research

HIV/AIDS Vaccine Likely Will Not Be Available Soon, Researcher Says

A Call for Continued HIV Vaccine Research

Bloomberg Examines HIV/AIDS Vaccine Research

AIDS Failure at Merck Elevates Burton Vaccine for 2 Million

A vaccine for AIDS – Is it time to concede defeat?

First Lady hosts Africa AIDS Vaccine Programme Roundtable

Vaccine Trials: Too Risky for U.S. Teens?

Commitment To Conducting More Basic Research in Search for HIV/AIDS Vaccine 'Prudent,' Editorial Says

Down, but not out

Balancing AIDS vaccine research

The great barrier

Vaccine Briefs

U.S. Researchers Scale Back HIV Vaccine Trial

Making AIDS Vaccine Trials More Effective

GeoVax Vaccine to Move Forward

AIDS Healthcare Foundation Leaders Support Reducing Vaccine Research

Defending Vaccine Research

Global Unity for HIV Vaccine

IAVI, CHAVI Join To Collaborate on HIV Vaccine Research

Vaccine Progress for HIV, Other Conditions Discussed at International Conference

Boston Trial to Test New HIV/AIDS Vaccine

Funding for Vaccine Research in Question

HIV/AIDS Vaccine Researchers at NIH Meeting Call for Increase in Basic Research, New Strategies

A Cure for HIV: Restoring Hope to a Long-Lost Cause

Now That Another HIV Vaccine Has Bitten the Dust, Where Do We Go From Here?

AIDS Healthcare Foundation Calls for End to U.S. Funding of HIV Vaccine Research

Time to Take a Step Back, Say Experts at HIV Vaccine Summit

Trials of NIH HIV Vaccine Candidate Scaled Down After Failure of Merck Vaccine

Testing A New HIV/AIDS Vaccine May Endanger Patients

Vaccine Failure Is Setback in AIDS

Pneumonia Vaccine Effective in HIV

Researchers Discover Protein That Could Lead to Development of HIV Vaccine, New Treatments, Study Says

U.S., British HIV/AIDS Researchers Pessimistic About Prospects of Vaccine, Survey Finds

HIV vaccine research hits impasse

Journal Articles and Publications by DAIDS/NIAID Staff

Improving Defences at the Portal of HIV Entry: Mucosal and Innate Immunity.

Broadening inclusion of vulnerable populations in HIV vaccine trials.

Social impact of preventive HIV vaccine clinical trial participation: A model of prevention, assessment and intervention.

Guidelines on Good Clinical Laboratory Practice: Bridging Operations between Research and Clinical Research Laboratories.

National Minority AIDS Council is a nonprofit organization www.nmac.org -- Main Office -- 1931 13th Street NW, Washington, DC 20009 (202) 483-6622 info@nmac.org

Satellite Office (Government Relations and Public Policy -- Communications/Media) -- 1624 U Street NW, Washington, DC 20009 (202) 234-5120

Disclaimer: This site contains HIV prevention messages that might be appropriate for all audiences. Since HIV infection is spread primarily through sexual practices or by sharing needles, prevention messages and programs may address these topics. If you are not seeking such information or may be offended by such materials, please exit this website.